Cite

    Home, P. et al. (2018). A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. Diabetes research and clinical practice. pp. 253-261. [Online].